← Oncology Approval Tracker

FDA DECISION ·

Aphexda + filgrastim

motixafortide + filgrastim · BioLineRx

FDA approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With filgrastim to mobilize blood-forming stem cells for collection and later autologous transplantation in patients with multiple myeloma.

LAMPGEN ANALYSIS

Why it matters

The approval adds a CXCR4-directed mobilization option before autologous transplant.

What research teams should watch

Coordinate dosing and premedication with the apheresis schedule and document collection yield.

PRIMARY RECORDS

Sources